Xconomy: Constellation Reboots With Eye On Immuno-Oncology, Hires New CEO
Summary
Constellation Pharmaceuticals, a Cambridge, MA-based biotech that up until 2015 had a sprawling alliance with Genentech, has made sweeping changes this morning.James Audia, the company’s chief scientific officer since 2011, will transition from his post in July.The company was formed nine years ago based on work into epigenetics, or the concept of switching genes on or off without changing the underlying DNA.Constellation believes it can develop drugs that may help overcome resistance to other immuno-oncology therapies and help open up those treatments to more patients, according to Raythatha.Dionne, who was an entrepreneur-in-residence at Third Rock before joining Constellation, was appointed shortly after the company signed a broad deal with Genentech in January 2012 to work together to develop epigenetic drugs for cancer.